McKesson Corporation (MCK)
NYSEHealth CareMedical - DistributionSnapshot 2026-10-29
NYSEHealth CareMedical - DistributionSnapshot 2026-10-29
Research Workspace
Put MCK beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Oncology & Multispecialty segment revenue growth: Comparison needs review.
View ThesisRevenue growth is slowing — up about 9% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 16%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskMcKesson’s growth case rests on expanding Oncology and Multispecialty, with recent revenue growth slowing. Revenue growth was 8% in Q1 FY2027, after 11% in Q3 FY2026; the latest quarter beat. MCK trades at 24× P/E versus a 22× peer median and its 21× historical multiple. The price reflects less growth than our forecast, despite that premium to peers. The next-quarter miss probability is 19%, and reported profits are not well backed by cash. Oncology and Multispecialty growth comparisons need review, so that pillar remains uncertain. Peer multiples imply a price about 7% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. MCK is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering MCK (as of Oct 2026).
Based on 7 Wall Street analysts offering 12-month price targets for MCK in the last 4 months.
Continue this research
Compare MCK with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MCK Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put MCK next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand Oncology & Multispecialty segment
Home-infusion bet supports Oncology & Multispecialty segment growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $980.88
The last 12 months of price, then the range of analyst 12-month targets from today’s $980.88.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Separate Medical-Surgical Solutions segment
Acquisition aligns with separating Medical-Surgical Solutions segment.
Advances: Separate Medical-Surgical Solutions segment
Acquisition supports growth in Medical-Surgical Solutions.

Acquisition aligns with growth strategy and expands portfolio.

Potential acquisition supports expansion in healthcare services.

Acquisition news indicates strategic growth in market presence.

Advances: Expand Oncology & Multispecialty segment
Extending CVS deal supports Oncology segment expansion.

Advances: Expand Oncology & Multispecialty segment
Oncology push aligns with segment expansion goals.
